Poolbeg Pharma Plc Stock Net Income
| POLBF Stock | USD 0.07 0.00 0.00% |
As of the 4th of March, Poolbeg Pharma holds the Risk Adjusted Performance of 0.1017, coefficient of variation of 812.4, and Variance of 46.72. Compared to fundamental indicators, the technical analysis model allows you to check existing technical drivers of Poolbeg Pharma, as well as the relationship between them. Please check Poolbeg Pharma PLC standard deviation, as well as the relationship between the treynor ratio and kurtosis to decide if Poolbeg Pharma PLC is priced some-what accurately, providing market reflects its current price of 0.0661 per share. As Poolbeg Pharma PLC appears to be a penny stock we also advise to check out its information ratio numbers.
Poolbeg Pharma's financial statements offer valuable quarterly and annual insights to potential investors, highlighting the company's current and historical financial position, overall management performance, and changes in financial standing over time. Key fundamentals influencing Poolbeg Pharma's valuation are provided below:Poolbeg Pharma PLC does not presently have any trending fundamental ratios for analysis. This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools. Poolbeg |
Poolbeg Pharma 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Poolbeg Pharma's pink sheet what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Poolbeg Pharma.
| 12/04/2025 |
| 03/04/2026 |
If you would invest 0.00 in Poolbeg Pharma on December 4, 2025 and sell it all today you would earn a total of 0.00 from holding Poolbeg Pharma PLC or generate 0.0% return on investment in Poolbeg Pharma over 90 days. Poolbeg Pharma is related to or competes with Paradigm Biopharmaceutica, Kintor Pharmaceutical, Satellos Bioscience, Imugene, Shield Therapeutics, Senzime AB, and Starpharma Holdings. Poolbeg Pharma plc operates as a clinical stage infectious disease pharmaceutical company in the United Kingdom More
Poolbeg Pharma Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Poolbeg Pharma's pink sheet current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Poolbeg Pharma PLC upside and downside potential and time the market with a certain degree of confidence.
| Information Ratio | 0.1162 | |||
| Maximum Drawdown | 55.53 |
Poolbeg Pharma Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for Poolbeg Pharma's investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Poolbeg Pharma's standard deviation. In reality, there are many statistical measures that can use Poolbeg Pharma historical prices to predict the future Poolbeg Pharma's volatility.| Risk Adjusted Performance | 0.1017 | |||
| Jensen Alpha | 0.8413 | |||
| Total Risk Alpha | 0.4975 | |||
| Treynor Ratio | (3.08) |
Poolbeg Pharma March 4, 2026 Technical Indicators
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | 0.1017 | |||
| Market Risk Adjusted Performance | (3.07) | |||
| Mean Deviation | 1.66 | |||
| Coefficient Of Variation | 812.4 | |||
| Standard Deviation | 6.84 | |||
| Variance | 46.72 | |||
| Information Ratio | 0.1162 | |||
| Jensen Alpha | 0.8413 | |||
| Total Risk Alpha | 0.4975 | |||
| Treynor Ratio | (3.08) | |||
| Maximum Drawdown | 55.53 | |||
| Skewness | 8.12 | |||
| Kurtosis | 66.0 |
Poolbeg Pharma PLC Backtested Returns
Poolbeg Pharma appears to be out of control, given 3 months investment horizon. Poolbeg Pharma PLC maintains Sharpe Ratio (i.e., Efficiency) of 0.13, which implies the firm had a 0.13 % return per unit of risk over the last 3 months. By analyzing Poolbeg Pharma's technical indicators, you can evaluate if the expected return of 0.9% is justified by implied risk. Please evaluate Poolbeg Pharma's Coefficient Of Variation of 812.4, variance of 46.72, and Risk Adjusted Performance of 0.1017 to confirm if our risk estimates are consistent with your expectations. On a scale of 0 to 100, Poolbeg Pharma holds a performance score of 10. The company holds a Beta of -0.27, which implies not very significant fluctuations relative to the market. As returns on the market increase, returns on owning Poolbeg Pharma are expected to decrease at a much lower rate. During the bear market, Poolbeg Pharma is likely to outperform the market. Please check Poolbeg Pharma's treynor ratio, kurtosis, as well as the relationship between the Kurtosis and day typical price , to make a quick decision on whether Poolbeg Pharma's historical price patterns will revert.
Auto-correlation | 0.00 |
No correlation between past and present
Poolbeg Pharma PLC has no correlation between past and present. Overlapping area represents the amount of predictability between Poolbeg Pharma time series from 4th of December 2025 to 18th of January 2026 and 18th of January 2026 to 4th of March 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Poolbeg Pharma PLC price movement. The serial correlation of 0.0 indicates that just 0.0% of current Poolbeg Pharma price fluctuation can be explain by its past prices.
| Correlation Coefficient | 0.0 | |
| Spearman Rank Test | 1.0 | |
| Residual Average | 0.0 | |
| Price Variance | 0.0 |
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
| Competition |
Based on the recorded statements, Poolbeg Pharma PLC reported net income of (3.11 Million). This is 100.91% lower than that of the Healthcare sector and 104.44% lower than that of the Biotechnology industry. The net income for all United States stocks is 100.54% higher than that of the company.
Poolbeg Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Poolbeg Pharma's direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the pink sheets which would be a good addition to a portfolio. Peer analysis of Poolbeg Pharma could also be used in its relative valuation, which is a method of valuing Poolbeg Pharma by comparing valuation metrics of similar companies.Poolbeg Pharma is currently under evaluation in net income category among its peers.
Poolbeg Fundamentals
| Shares Outstanding | 500 M | |||
| Shares Owned By Insiders | 19.57 % | |||
| Shares Owned By Institutions | 6.95 % | |||
| EBITDA | (3.24 M) | |||
| Net Income | (3.11 M) | |||
| Cash And Equivalents | 18.89 M | |||
| Cash Per Share | 0.04 X | |||
| Current Ratio | 48.98 X | |||
| Book Value Per Share | 0.04 X | |||
| Cash Flow From Operations | (2.86 M) | |||
| Market Capitalization | 60.65 M |
About Poolbeg Pharma Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Poolbeg Pharma PLC's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Poolbeg Pharma using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Poolbeg Pharma PLC based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
| FSLY | Fastly Class A | |
| MOB | Mobilicom Limited American | |
| CMG | Chipotle Mexican Grill | |
| CSAN | Cosan SA ADR | |
| RKT | Rocket Companies |
Other Information on Investing in Poolbeg Pink Sheet
Poolbeg Pharma financial ratios help investors to determine whether Poolbeg Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Poolbeg with respect to the benefits of owning Poolbeg Pharma security.